Rossari Biotech Q1 FY27 Revenue Surges 28% YoY to ₹697.2 Crore, Highest Ever Quarterly Revenue
Rossari Biotech reported Q1 FY27 consolidated revenue of ₹697.2 crore, up 28% YoY. EBITDA increased 19% to ₹80.6 crore, and PAT grew 4% to ₹35.1 crore. Standalone revenue rose 32% to ₹482.3 crore. The company established a new facility in Thailand and sold its Andheri office.
The announcement details significant financial growth, including record revenue and EBITDA, alongside strategic expansion and asset monetization, which are material events for investors and stakeholders.
The company reported record quarterly revenue and EBITDA, along with significant year-on-year growth in revenue and PAT, indicating strong financial performance. Expansion into new markets and strategic asset monetization also contribute positively.
Rossari Biotech Limited announced its financial results for the quarter ended June 30, 2026, reporting its highest-ever quarterly revenue of ₹697.2 crore, a 28% year-on-year increase from ₹543.7 crore in Q1 FY26.
Consolidated EBITDA improved by 19% to ₹80.6 crore from ₹67.9 crore, though the EBITDA margin slightly decreased to 11.6% from 12.5%. Profit After Tax (PAT) saw a 4% rise to ₹35.1 crore, compared to ₹33.6 crore in the prior year's quarter. Diluted Earnings Per Share (EPS) stood at ₹6.3*.
On a standalone basis, revenue from operations grew by 32% to ₹482.3 crore from ₹365.8 crore. Standalone EBITDA increased by 28% to ₹56.4 crore, with an EBITDA margin of 11.7%. PAT surged by 31% to ₹34.3 crore, and diluted EPS was ₹6.2.
Management highlighted robust consolidated revenue growth driven by healthy domestic business momentum and international expansion. The company's diversified business model and disciplined execution contributed to growth across all segments, with HPPC, TSC, and AHN businesses showing strong YoY growth. The establishment of a new greenfield blending facility in Thailand, with a capacity of 5,000 MTPA, is expected to enhance customized formulation offerings and supply chain efficiency in Southeast Asia.
Key developments include progress on the monetization of non-core assets with the sale of the Andheri office, following the sale of the Kanjurmarg office in the previous quarter. The company remains focused on disciplined execution, innovation, profitable growth, and optimizing capacity utilization.
What to do with a filing like this
Rossari Biotech Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Rossari Biotech Limited. Read the original for the full detail.